2 results
Approved WMOCompleted
The primary study objective is to compare the rate of major CIED infections through 12-months post-implant between the TYRX envelope group and the control group.
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.